thymus, brain and testes associatedGenealiases: C10orf27 · SPATIAL
Q-omics provides the consensus-scored TBATA profile across patient tissues and cancer cell-line models. TBATA expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TBATA is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TBATA RNA expression shows 6,672 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, KIRC, and STAD as cancer lineages where TBATA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBATA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBATA survival associations across molecular data types. TBATA RNA expression shows survival associations in the most cancer types (17), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBATA RNA expression–survival associations across cancer types. High TBATA expression shows unfavorable associations in UVM, ACC, LIHC and LGG, but favorable associations in LUAD and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TBATA RNA expression.
This table summarizes TBATA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TBATA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBATA shows lower tumor expression in KIRC, KIRP and COAD and higher tumor expression in KICH, LUSC and LUAD. The KIRC box plot shows higher TBATA RNA expression in normal versus tumor tissue (log2 FC = −0.139, t-test p < 0.001).
This table shows molecular features associated with TBATA in patient tissues and cancer cell lines. In patient samples, TBATA shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TBATA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and OVARY.
